| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
|
Eur Heart J
|
2012
|
18.18
|
|
2
|
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
|
Eur Heart J
|
2013
|
9.54
|
|
3
|
Thrombus aspiration during ST-segment elevation myocardial infarction.
|
N Engl J Med
|
2013
|
8.13
|
|
4
|
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
|
N Engl J Med
|
2007
|
4.95
|
|
5
|
Outcomes 1 year after thrombus aspiration for myocardial infarction.
|
N Engl J Med
|
2014
|
2.17
|
|
6
|
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2013
|
2.14
|
|
7
|
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
|
Circulation
|
2013
|
2.03
|
|
8
|
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
|
J Am Coll Cardiol
|
2010
|
2.00
|
|
9
|
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
|
Eur Heart J
|
2011
|
1.98
|
|
10
|
Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation).
|
JACC Cardiovasc Interv
|
2011
|
1.88
|
|
11
|
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
|
Circulation
|
2012
|
1.84
|
|
12
|
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
|
Circulation
|
2013
|
1.77
|
|
13
|
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
|
Circulation
|
2012
|
1.62
|
|
14
|
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
|
Eur Heart J
|
2009
|
1.55
|
|
15
|
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
|
Circulation
|
2011
|
1.46
|
|
16
|
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
|
JACC Cardiovasc Interv
|
2013
|
1.46
|
|
17
|
Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
|
J Am Coll Cardiol
|
2010
|
1.44
|
|
18
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
19
|
Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry.
|
Circ Cardiovasc Interv
|
2009
|
1.25
|
|
20
|
2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management.
|
Heart
|
2013
|
1.25
|
|
21
|
Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale.
|
Am Heart J
|
2010
|
1.22
|
|
22
|
Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. A report of more than 90,000 stent implantations.
|
PLoS One
|
2013
|
1.17
|
|
23
|
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
|
Circulation
|
2011
|
1.13
|
|
24
|
Comparison of two drug-eluting balloons: a report from the SCAAR registry.
|
EuroIntervention
|
2012
|
1.12
|
|
25
|
Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial.
|
Arch Intern Med
|
2011
|
1.06
|
|
26
|
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
|
Eur Heart J
|
2011
|
1.05
|
|
27
|
ST2 and mortality in non-ST-segment elevation acute coronary syndrome.
|
Am Heart J
|
2010
|
1.03
|
|
28
|
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
|
Eur Heart J
|
2007
|
1.01
|
|
29
|
P2Y12 platelet inhibition in clinical practice.
|
J Thromb Thrombolysis
|
2012
|
0.97
|
|
30
|
Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
|
J Am Coll Cardiol
|
2009
|
0.96
|
|
31
|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
|
Platelets
|
2013
|
0.91
|
|
32
|
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
|
Clin Chem
|
2011
|
0.90
|
|
33
|
Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
|
J Am Coll Cardiol
|
2013
|
0.89
|
|
34
|
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
|
Am J Cardiol
|
2011
|
0.88
|
|
35
|
Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome.
|
Clin Biochem
|
2013
|
0.86
|
|
36
|
Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria.
|
J Am Coll Cardiol
|
2009
|
0.86
|
|
37
|
NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO).
|
Circ Cardiovasc Genet
|
2015
|
0.82
|
|
38
|
Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial.
|
Circ Cardiovasc Qual Outcomes
|
2012
|
0.82
|
|
39
|
Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
|
Clin Chem
|
2013
|
0.81
|
|
40
|
Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
|
EuroIntervention
|
2016
|
0.79
|
|
41
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
42
|
Proximal coronary artery intervention: stent thrombosis, restenosis and death.
|
Int J Cardiol
|
2013
|
0.78
|
|
43
|
Thrombus aspiration in ST-elevation myocardial infarction in Sweden: a short report on real world outcome.
|
Int J Cardiol
|
2010
|
0.78
|
|
44
|
Thrombus aspiration during myocardial infarction.
|
N Engl J Med
|
2014
|
0.77
|
|
45
|
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
|
Am Heart J
|
2013
|
0.76
|
|
46
|
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
|
Am Heart J
|
2013
|
0.76
|
|
47
|
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
|
Circulation
|
2014
|
0.75
|
|
48
|
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
|
Stroke
|
2013
|
0.75
|
|
49
|
Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART.
|
EuroIntervention
|
2016
|
0.75
|
|
50
|
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
|
Am Heart J
|
2011
|
0.75
|
|
51
|
Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts.
|
Am Heart J
|
2012
|
0.75
|
|
52
|
Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.
|
EuroIntervention
|
2017
|
0.75
|
|
53
|
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
|
Am Heart J
|
2012
|
0.75
|
|
54
|
Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician.
|
J Thromb Thrombolysis
|
2010
|
0.75
|